Fadi Fakhouri
Fadi Fakhouri has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Véronique Frémeaux-Bacchi
INSERM UMR S1138, Complément et Maladies, Centre de recherche des Cordeliers, and Laboratory of Immunology, Hôpital Européen Georges Pompidou, Paris, France
10 shared publicationsChantal Loirat
Department of Pediatric Nephrology, Centre Hospitalier Universitaire Robert Debré
5 shared publicationsFrançois Provôt
Department of Nephrology and Immunology, Center Hospitalier Universitaire de Nantes, Nantes, France
5 shared publicationsYahsou Delmas
Department of Nephrology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
5 shared publicationsAlexandre Karras
Department of Nephrology, Centre Hospitalier Universitaire, Hôpital Européen Georges Pompidou, Paris, France
3 shared publicationsAnne Moreau
Department of pathology, Centre Hospitalier Universitaire, Nantes, France
3 shared publications
Latest Publications
- 1 March 2020
- Published by Elsevier in Kidney International
- Vol. 97 (3) , 621-622
The Case | A neoplastic cause of acute kidney injury
- 1 March 2020
- Published by Elsevier in Kidney International
- Vol. 97 (3) , 621-622
The Case | A neoplastic cause of acute kidney injury
- 1 December 2019
- Published by Elsevier in Kidney International
- Vol. 96 (6) , 1423-1424
Shiga toxin–producing Escherichia coli–associated hemolytic uremic syndrome in solid organ transplant recipients
- 1 December 2019
- Published by Elsevier in Kidney International
- Vol. 96 (6) , 1423-1424
Shiga toxin–producing Escherichia coli–associated hemolytic uremic syndrome in solid organ transplant recipients
- 1 August 2019
- Published by Elsevier in Kidney International
- Vol. 96 (2) , 517-518
The authors reply
- 1 June 2019
- Published by Elsevier in Kidney International
- Vol. 95 (6) , 1443-1452
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors
- 1 June 2019
- Published by Elsevier in Kidney International
- Vol. 95 (6) , 1443-1452
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors
- Open Access
- 10 April 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-12
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with eculizumab. Patients with aHUS who participated in any of five parent eculizumab trials and received at least one eculizumab infusion were eligible for enrollment in a long-term follow-up study. Rates of thrombotic microangiopathy (TMA) manifestations off versus on eculizumab were evaluated. Additional endpoints included change from baseline estimated glomerular filtration rate (eGFR), long-term renal outcomes, and serious targeted treatment-emergent adverse events. Among 93 patients (0–80 years of age), 51 (55%) remained on eculizumab and 42 (45%) discontinued; for those who discontinued, 21 (50%) reinitiated therapy. Patients who reinitiated eculizumab had similar baseline clinical characteristics to patients who remained on eculizumab, with higher likelihood of genetic/autoimmune complement abnormalities, more prior TMAs, and longer disease course versus those who did not reinitiate. Mean eGFR improved rapidly and remained stable for up to 6 years on eculizumab. In patients who discontinued, there was a trend toward decreasing renal function over time from discontinuation. Additionally, off-treatment TMA manifestation rates were higher in those aged < 18 years at diagnosis, with identified genetic/autoimmune complement abnormalities, or history of multiple TMAs prior to eculizumab initiation. The safety profile was consistent with previous studies. Three definite and one possible meningococcal infections related to eculizumab were reported and resolved with treatment. Three deaths unrelated to eculizumab were reported. The current study confirms the efficacy and safety of eculizumab in aHUS, particularly with regard to long-term renal function and TMA events. Pediatric age at disease onset and presence of genetic or autoimmune complement abnormalities are risk factors for TMA events off treatment. Overall, patients who discontinue eculizumab may be at risk for additional TMA manifestations and renal function decreases. Discontinuation of eculizumab, with careful monitoring, is an option in select patients with consideration of patient preference, organ function normalization, and risk factors for relapse, including mutational analysis, age of onset, and history of multiple TMA episodes. ClinicalTrials.gov NCT01522170 , January 31, 2012.
- 10 April 2019
- Published by Springer Nature in BMC Nephrology
- Vol. 20 (1) , 1-12
Open AccessOutcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with eculizumab. Patients with aHUS who participated in any of five parent eculizumab trials and received at least one eculizumab infusion were eligible for enrollment in a long-term follow-up study. Rates of thrombotic microangiopathy (TMA) manifestations off versus on eculizumab were evaluated. Additional endpoints included change from baseline estimated glomerular filtration rate (eGFR), long-term renal outcomes, and serious targeted treatment-emergent adverse events. Among 93 patients (0–80 years of age), 51 (55%) remained on eculizumab and 42 (45%) discontinued; for those who discontinued, 21 (50%) reinitiated therapy. Patients who reinitiated eculizumab had similar baseline clinical characteristics to patients who remained on eculizumab, with higher likelihood of genetic/autoimmune complement abnormalities, more prior TMAs, and longer disease course versus those who did not reinitiate. Mean eGFR improved rapidly and remained stable for up to 6 years on eculizumab. In patients who discontinued, there was a trend toward decreasing renal function over time from discontinuation. Additionally, off-treatment TMA manifestation rates were higher in those aged < 18 years at diagnosis, with identified genetic/autoimmune complement abnormalities, or history of multiple TMAs prior to eculizumab initiation. The safety profile was consistent with previous studies. Three definite and one possible meningococcal infections related to eculizumab were reported and resolved with treatment. Three deaths unrelated to eculizumab were reported. The current study confirms the efficacy and safety of eculizumab in aHUS, particularly with regard to long-term renal function and TMA events. Pediatric age at disease onset and presence of genetic or autoimmune complement abnormalities are risk factors for TMA events off treatment. Overall, patients who discontinue eculizumab may be at risk for additional TMA manifestations and renal function decreases. Discontinuation of eculizumab, with careful monitoring, is an option in select patients with consideration of patient preference, organ function normalization, and risk factors for relapse, including mutational analysis, age of onset, and history of multiple TMA episodes. ClinicalTrials.gov NCT01522170 , January 31, 2012.
- 1 July 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 72 (1) , 84-92
Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy
- 1 July 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 72 (1) , 84-92
Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy
- 25 October 2017
- Published by Springer Nature in Médecine Intensive Réanimation
- Vol. 26 (6) , 456-463
Les glomérulonéphrites membranoprolifératives primitives : quelques considérations cliniques à propos d’un cas
- 25 October 2017
- Published by Springer Nature in Médecine Intensive Réanimation
- Vol. 26 (6) , 456-463
Les glomérulonéphrites membranoprolifératives primitives : quelques considérations cliniques à propos d’un cas
- 27 September 2017
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 30 (6) , 767-771
Pregnancy-related acute kidney injury in high income countries: still a critical issue
The rate of pregnancy-associated acute kidney injury (P-AKI) has dwindled in high income countries mainly following the legalization of abortion in the seventies and early eighties and the general improvement in obstetrical care. P-AKI has not however disappeared from high income countries and several reports indicate that its frequency has even increased during the last decade. The reasons for such evolution are probably an improved surveillance and reporting of P-AKI and a more aggressive approach to the treatment of pregnancy complications, with unintended renal side effects. The characteristics of pregnant women in high-income countries have also changed as the number of women with medical conditions, including diabetes and chronic kidney disease, has tended to increase. P-AKI in high income countries is still a matter of concern for nephrologists who have in mind that any rate, however low, of P-AKI remains unacceptable.
- 27 September 2017
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 30 (6) , 767-771
Pregnancy-related acute kidney injury in high income countries: still a critical issue
The rate of pregnancy-associated acute kidney injury (P-AKI) has dwindled in high income countries mainly following the legalization of abortion in the seventies and early eighties and the general improvement in obstetrical care. P-AKI has not however disappeared from high income countries and several reports indicate that its frequency has even increased during the last decade. The reasons for such evolution are probably an improved surveillance and reporting of P-AKI and a more aggressive approach to the treatment of pregnancy complications, with unintended renal side effects. The characteristics of pregnant women in high-income countries have also changed as the number of women with medical conditions, including diabetes and chronic kidney disease, has tended to increase. P-AKI in high income countries is still a matter of concern for nephrologists who have in mind that any rate, however low, of P-AKI remains unacceptable.
- 10 July 2017
- Published by Wiley in European Journal of Immunology
- Vol. 47 (8) , 1368-1376
Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28
Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory disease. Autoantibodies (autoAbs) against double‐stranded DNA (ds DNA), the hallmark of lupus, are produced and maintained by the interaction between auto‐reactive B cells and CD4+ T cells. This interplay is controlled by the CD28/CD80‐86/CTLA‐4 axis. Here we investigated whether selective blockade of CD28‐CD80/86 co‐stimulatory interactions abrogates lupus nephritis development in a murine model of SLE. To this aim, NZB/NZW F1 mice were treated for 3 months, either with an anti‐CD28 Fab’ fragment or a control Fab’‐IgG. The effect of CD28 blockade on lupus nephritis onset, survival, production of anti‐ds DNA antibodies and costimulatory molecules was evaluated. CD28 blockade prevented the development of lupus nephritis and prolonged survival during the 3‐month treatment and 12 weeks after. Furthermore, the production of anti‐ds DNA autoAbs was decreased. Lastly, the protective effect of CD28 blockade was associated with increased intrarenal expression of the immunoregulatory molecule, Indoleamine 2, 3‐dioxygenase, of the co‐inhibitory receptor programmed cell‐Death – 1 (PD‐1) and of its ligand programmed death ligand ‐ 1 (PDL‐1).In conclusion, CD28 blockade prevented the development of lupus nephritis in NZB/NZW F1 mice. This immunomodulatory strategy is a promising candidate for SLE therapy in humans.
- 10 July 2017
- Published by Wiley in European Journal of Immunology
- Vol. 47 (8) , 1368-1376
Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28
Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory disease. Autoantibodies (autoAbs) against double‐stranded DNA (ds DNA), the hallmark of lupus, are produced and maintained by the interaction between auto‐reactive B cells and CD4+ T cells. This interplay is controlled by the CD28/CD80‐86/CTLA‐4 axis. Here we investigated whether selective blockade of CD28‐CD80/86 co‐stimulatory interactions abrogates lupus nephritis development in a murine model of SLE. To this aim, NZB/NZW F1 mice were treated for 3 months, either with an anti‐CD28 Fab’ fragment or a control Fab’‐IgG. The effect of CD28 blockade on lupus nephritis onset, survival, production of anti‐ds DNA antibodies and costimulatory molecules was evaluated. CD28 blockade prevented the development of lupus nephritis and prolonged survival during the 3‐month treatment and 12 weeks after. Furthermore, the production of anti‐ds DNA autoAbs was decreased. Lastly, the protective effect of CD28 blockade was associated with increased intrarenal expression of the immunoregulatory molecule, Indoleamine 2, 3‐dioxygenase, of the co‐inhibitory receptor programmed cell‐Death – 1 (PD‐1) and of its ligand programmed death ligand ‐ 1 (PDL‐1).In conclusion, CD28 blockade prevented the development of lupus nephritis in NZB/NZW F1 mice. This immunomodulatory strategy is a promising candidate for SLE therapy in humans.
- Open Access
- 8 June 2017
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 12 (8) , 1237-1247
Hemolytic Uremic Syndrome in Pregnancy and Postpartum
Background: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation. Design, setting, participants, & measurements: We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome. Results: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%). Conclusions: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.
- 8 June 2017
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 12 (8) , 1237-1247
Open AccessHemolytic Uremic Syndrome in Pregnancy and Postpartum
Background: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation. Design, setting, participants, & measurements: We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome. Results: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%). Conclusions: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.